01:09 , Aug 23, 2019 |  BC Innovations  |  Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Antitope, Rottapharm Madaus deal

Antitope said it completed a research deal with Rottapharm's antibody unit Rottapharm Biotech s.r.l. to profile the immunogenicity of Rottapharm's CRB0017 . Under the deal, Antitope applied its EpiScreen and in silico iTope/TCED technologies in...